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http://www.jbiomedsci.com/content/21/1/73RESEARCH Open AccessPromoter methylation analysis of WNT/β-catenin
pathway regulators and its association with
expression of DNMT1 enzyme in colorectal cancer
Nader Mansour Samaei1, Yaghoub Yazdani1, Reza Alizadeh-Navaei2, Hossein Azadeh3 and Touraj Farazmandfar1,2,3*Abstract
Background: Aberrant DNA methylation as the most important reason making epigenetic silencing of genes is a
main mechanism of gene inactivation in patients with colorectal cancer. In this study, we decided to identify
promoter methylation status of ten genes encoding WNT negative regulators, and measure the expression of
DNMT1 enzyme in colorectal cancer samples.
Results: Aberrant methylation of APC gene was statistically significant associated with age over 50 (p = 0.017), DDK3
with male (p < 0.0001), SFRP4, WIF1, and WNT5a with increasing tumor stage (p = 0.004, p = 0.029, and p = 0.004),
SFRP4 and WIF1 with tumor differentiation (p = 0.009 and p = 0.031) and SFRP2 and SFRP5 with histological type
(p = 0.001 and p = 0.025). The increasing number of methylated genes correlated with the expression levels of the
DNMT1 mRNA.
Conclusions: The rate of gene promoter methylation of WNT pathway regulators is high in colorectal cancer cells.
Hyper-methylation is associated with increased expression of the DNMT1 enzyme.
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Colorectal cancer (CRC) is the second-leading cause of
cancer deaths among adults [1]. Aberrant DNA methy-
lation as the most important reason of epigenetic gene
silencing is the main mechanism of gene inactivation in
patients with CRC [2,3]. Methylation normally occurs in
5-carbon position of cytosine base within CpG dinucleotide
in areas of repetitive DNA outside of exons, introduced
by DNA methylases; mainly DNA methyltransferase 1
(DNMT1). Although the DNMT1 enzyme is not the
only factor involving in the DNA methylation, but plays
a significant role in creating it [4-6]. DNA methylation
of CpG islands in promoter regions of tumor suppressor
genes and DNA repair genes is now recognized as a
prevalent feature of human cancers [2].* Correspondence: tourajf@yahoo.com
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article, unless otherwise stated.The developmental WNT/β-catenin signaling pathway
is one of the well-known signaling pathways involved in
embryogenesis and cancer. A common mechanism of
carcinogenesis through WNT/β-catenin signaling is the
increased levels of β-catenin protein, which are often
results from mutations in the adenomatous polyposis
coli (APC) gene (encoding a β-catenin inhibitor) or in
the β-catenin gene. Moreover, other mechanisms like
functional reduction or loss of negative regulators by
DNA methylation or overexpression of oncogenic ligands
may contribute to WNT pathway activation in cancer
development [7-9]. In previous studies, DNA methylation
of some WNT inhibitors such as APC, axis inhibition
protein 2 (AXIN2), secreted frizzled-related protein (SFRP)
family and members of the DICKKOPF (DKK) have been
reported in CRC [10-13].
As of yet, no comprehensive survey on promoter
methylation levels of WNT pathway inhibitors in CRC
has been performed, while a potential use of promoter
methylation in cancer diagnosis and prediction can be
highly regarded. In this study, promoter methylation
status of ten genes encoding WNT negative regulatorsd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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extracellular WNT inhibitors [WNT inhibitory factor-1
(WIF1), DKK3, SFRP2, SFRP4, SFRP5], cytosolic WNT
antagonists (AXIN2, APC), nuclear proteins [sex deter-
mining region Y related box 7 (SOX7) and 17 (SOX17)],
and one WNT ligand [wingless-type MMTV integration
site family member 5A (WNT5A)]. To estimate the associ-
ation between methylation and expression of the DNMT1




Samples including 125 Formalin-fixed paraffin-embedded
(FFPE) cancerous and adjacent normal tissues (normal
tissues distances from the tumor were not measured in
this study) obtained from the CRC patients who had
surgery between 2005 and 2011 from pathology laboratory.
Clinical and pathologic features of patients were extracted
from medical records and Tumor staging was determined
on the basis of the tumor node metastasis (TNM) classifi-
cation [14]. Samples with mutational familial adenomatous
polyposis or hereditary non-polyposis CRC were excluded
of this study. This study was approved of the Clinical
Research Ethics Committee in Golestan University of
Medical Science.
Methylation analysis
Genomic DNA of microdissected tissue samples was
extracted and bisulfite treated using the EpiTect Fast
Bisulfite Conversion Kit (Qiagen, Hilden, Germany).
Methylation specific PCR (MSP) primers of 10 selected
candidate genes were prepared as described previously
[15]. MSP was performed using 50 nanograms of modi-
fied DNA and Taq DNA polymerase (Roche, Woerden,
Netherlands) in 7500 Real-Time PCR system (Applied
Biosystem, USA). The methylation was calculated from
threshold cycles (CT) values. Ten MSPs for the WNT
inhibitors were analytically validated using methylated
DNA as positive control (CTs ≤ 25 cycles) and primary
keratinocyte DNA as unmethylated controls (CTs >
35 cycles).
DNMT1 expression assay
The amplification primers for human DNMT1 and
Hypoxanthine-guanine phosphoribosyltransferase (HPRT)
cDNA designed by GENE RUNNER software and be
reviewed in NCBI and BLAST. DNMT1 Primers sequence
including 5′-AGCCAGGTAGCCCTCCTC-3′ as forward
and 5′-GACAGCTTAACAGAAAAGGAATG-3′ as re-
verse with a 141 base pairs (bp) PCR product (GenBank
accession number NM_001379.1) and HPRT including
5′-TGGACTAATTATGGACAGGACT-3′ as forward and
5′-CCTGTTGACTGGTCATTACAAT-3′ as reverse witha 219 bp PCR product (GenBank accession number
NM_000194). Total RNA was purified from micro-
dissected FFPE tissues using the PureLink FFPE RNA
Isolation Kit (Invitrogen, Karlsruhe, Germany). The first
strand cDNA was generated using a SuperScript III
First-Strand Synthesis SuperMix (Invitrogen, Karlsruhe,
Germany). Reverse transcriptase PCR was performed using
SYBR Green PCR Master Mix (Fermentas, Lithuania)
in triplicate and normalized to HPRT in 7500 detection
system. Real-Time PCR conditions consist of 40 cycles
(95°C for 15 s, 55°C for 30 s, 72°C for 20 s) after one step
initial denaturation (95°C for 10 min). The mean and
standard deviation (SD) of DNMT1 mRNA was calculated
by 2-ΔCT and the expression fold was calculated by the
2-ΔΔCT and a fold change ≥1.5 was considered as over-
expression [16].
Statistical analysis
Statistical analysis was performed by SPSS (version 17.0).
Methylation frequencies associations with clinical and
pathologic features were analyzed using chi-squared and
fisher’s exact test. The survival curves were estimated by
the Kaplan-Meier method. Association between promoter
methylation status with survival was examined by the
log-rank test. Survival time was determined from the
diagnosis date to the death date due to CRC. A p-value
of less than 0.05 was considered statistically significant.
Results
The promoter methylation status
In this study, the promoter methylation was examined
on ten genes encoding the WNT pathway inhibitors in
CRC tissue samples. Aberrant promoter methylation was
detected in 78.4% of patients (98 of 125) (CTs ≤ 25) and
none of adjacent non-tumor samples showed methylation
(CTs > 35 cycles). The promoter methylation status of the
ten genes, including APC, AXIN2, DKK3, SFRP2, SFRP4,
SERP5, SOX7, SOX17, WIF1 and WNT5a are respectively
44 samples (35.2%), 41 (32.8%), 50 (40%), 58 (46.4%), 38
(28.8%), 33 (26.4%), 40 (32%), 42 (33.6%), 52 (41.6%) and
28 (22.4%) (Table 1).
The correlation with clinical and pathological features
We analyzed methylation status relationship of these genes
with some patients’ clinical and pathological features.
As the results in Table 1 show, APC gene methylation
is statistically associated with age over 50 (p = 0.017).
DDK3 gene methylation is also significantly associated
with male (p < 0.0001). Methylation of SFRP4, WIF1
and WNT5a genes were meaningfully associated with
increasing tumor stage (p = 0.004, p = 0.029 and p = 0.004).
Moreover, methylation frequency of SFRP4 andWIF1 genes
were also significantly associated with tumor differentiation
(p = 0.009 and p = 0.031). The SFRP2 and SFRP5 genes
Table 1 The association of promoter methylation frequencies and DNMT1 expression with some pathological and clinical features of patients
Clinical and
pathological features
N APC AXIN2 DKK3 SFRP2 SFRP4 SFRP5
N (%) N (%) N (%) N (%) N (%) N (%)
M U p M U P M U p M U p M U p M U p
All cases 125 44 (35.2) 81 (64.8) 41 (32.8) 84 (67.2) 50 (40) 75 (60) 58 (46.4) 67 (53.6) 38 (30.4) 87 (69.6) 33 (26.4) 92 (73.6)
Age .017
<50 18 11 (25) 7 (8.7) 7 (17.1) 11 (13.1) 8 (16) 10 (13.3) 9 (15.5) 9 (13.4) 5 (13.2) 13 (14.9) 8 (24.2) 10 (10.7)
≥50 107 33 (75) 74 (91.3) 34 (82.9) 73 (86.9) 42 (84) 65 (86.7) 49 (84.5) 58 (86.6) 33 (86.8) 74 (85.1) 25 (75.8) 82 (89.3)
Sex <.001
Female 55 21 (47.7) 34 (42) 16 (39) 39 (46.4) 12 (24) 43 (57.3) 28 (48.3) 27 (40.3) 13 (34.2) 42 (48.3) 17 (51.5) 38 (41.3)
Male 70 23 (52.3) 47 (58) 25 (61) 45 (53.6) 38 (76) 32 (42.7) 30 (51.7) 40 (59.7) 25 (65.8) 45 (51.7) 16 (48.5) 54 (58.7)
Tumor location
Proximal 58 18 (40.9) 40 (49.2) 19 (46.3) 39 (46.4) 24 (48) 34 (45.3) 32 (55.1) 26 (38.8) 17 (44.7) 41 (47.1) 16 (48.5) 42 (45.7)
Distal 67 26 (59.1) 41 (50.8) 22 (53.7) 45 (53.6) 26 (52) 41 (54.7) 26 (44.9) 41 (61.2) 21 (55.3) 46 (52.9) 17 (51.5) 50 (54.3)
TNM stage .004
I 17 5 (11.4) 12 (14.8) 6 (14.6) 11 (13.1) 8 (16) 9 (12) 9 (15.5) 8 (11.9) 4 (10.5) 13 (14.9) 5 (15.2) 12 (13)
II 39 17 (38.6) 22 (27.2) 11 (26.8) 28 (33.3) 15 (30) 24 (32) 18 (31) 21 (31.3) 10 (26.3) 29 (33.3) 12 (36.4) 27 (29.3)
III 61 18 (40.9) 43 (53.1) 19 (46.4) 42 (50) 22 (44) 39 (52) 25 (43.1) 36 (53.8) 17 (44.7) 44 (50.6) 13 (39.4) 48 (52.2)
IV 8 4 (9.1) 4 (4.9) 5 (12.2) 3 (3.6) 5 (10) 3 (4) 6 (10.4) 2 (3) 7 (18.5) 1 (1.2) 3 (9) 5 (5.5)
Tumor differentiation .009
Low 11 4 (9.1) 7 (8.7) 5 (12.2) 6 (7.1) 3 (6) 8 (10.7) 4 (6.9) 7 (10.4) 6 (15.8) 5 (5.7) 3 (9.1) 8 (8.7)
Moderate 89 30 (68.2) 59 (72.8) 27 (65.9) 62 (73.8) 39 (78) 50 (66.7) 43 (74.1) 46 (68.7) 20 (52.6) 69 (79.3) 22 (66.7) 67 (72.8)
High 25 10 (22.7) 15 (18.5) 9 (21.9) 16 (19.1) 8 (16) 17 (22.6) 11 (19) 14 (20.9) 12 (31.6) 13 (15) 8 (24.2) 17 (18.5)
Histological type .001 .025
Non-mucinous 98 30 (68.2) 68 (84) 34 (82.9) 64 (76.2) 39 (78) 59 (78.7) 53 (91.4) 45 (67.2) 30 (78.9) 68 (78.2) 21 (63.6) 77 (83.7)



















SOX7 SOX17 WIF1 WNT5a DNMT1 expression
N (%) N (%) N (%) N (%) Fold change (%)
M U p M U p M U p M U p ≥1.5 <1.5 p
All cases 40 (32) 85 (68) 42 (33.6) 83 (66.4) 52 (41.6) 73 (58.4) 28 (22.4) 97 (77.6) 52 (41.6) 73 (58.4)
Age
<50 7 (17.5) 11 (12.5) 10 (23.8) 8 (9.6) 5 (9.6) 13 (17.8) 6 (21.4) 12 (12.4) 7 (13.5) 11 (15.1)
≥50 33 (82.5) 74 (87.5) 32 (76.2) 75 (90.4) 47 (90.4) 60 (82.2) 22 (78.6) 85 (87.6) 45 (86.5) 62 (84.9)
Sex
Female 19 (47.5) 36 (42.4) 15 (35.7) 40 (48.2) 23 (44.2) 32 (43.8) 12 (42.8) 43 (44.3) 21 (40.4) 34 (46.6)
Male 21 (52.5) 49 (57.6) 27 (64.3) 43 (51.8) 29 (55.8) 41 (56.2) 16 (57.2) 54 (55.7) 31 (59.6) 39 (53.4)
Tumor location
Proximal 21 (52.5) 37 (43.5) 20 (47.6) 38 (45.8) 27 (51.9) 31 (42.5) 14 (50) 44 (45.4) 28 (53.8) 30 (41.1)
Distal 19 (47.5) 48 (56.5) 22 (52.4) 45 (54.2) 25 (48.1) 42 (57.5) 14 (50) 53 (54.6) 24 (46.2) 43 (58.9)
TNM stage .029 .004
I 7 (17.5) 10 (11.8) 6 (14.3) 11 (13.3) 12 (23.1) 5 (6.8) 3 (10.7) 14 (14.4) 7 (13.5) 10 (13.7)
II 13 (32.5) 26 (30.6) 10 (23.8) 29 (34.9) 14 (26.9) 25 (34.3) 5 (17.8) 34 (35.1) 13 (25) 26 (35.6)
III 16 (40) 45 (52.9) 24 (57.1) 37 (44.6) 25 (48.1) 36 (49.3) 14 (50) 47 (48.4) 27 (51.9) 34 (46.6)
IV 4 (10) 4 (4.7) 2 (4.8) 6 (7.2) 1 (1.9) 7 (9.6) 6 (21.5) 2 (2.1) 5 (9.6) 3 (4.1)
Tumor differentiation .031
Low 2 (5) 9 (10.6) 7 (16.7) 4 (4.8) 1 (1.9) 10 (13.7) 3 (10.7) 8 (8.2) 4 (7.7) 7 (9.6)
Moderate 32 (80) 57 (67.1) 30 (71.4) 59 (71.1) 37 (71.2) 52 (71.2) 18 (64.3) 71 (73.2) 36 (69.2) 53 (72.6)
High 6 (15) 19 (22.3) 5 (11.9) 20 (24.1) 14 (26.9) 11 (15.1) 7 (25) 18 (18.6) 12 (23.1) 13 (17.8)
Histological type
Non-mucinous 34 (85) 64 (75.3) 32 (76.1) 66 (79.5) 37 (71.2) 61 (83.6) 19 (67.8) 79 (81.4) 35 (67.3) 63 (86.3)
Mucinous 6 (15) 21 (24.7) 10 (23.9) 17 (20.5) 15 (28.8) 12 (16.4) 9 (32.2) 18 (18.6) 17 (32.7) 10 (13.7)
N; Number of cases, M; Methylated, U; Unmethylated, p; p value.

















Figure 1 Kaplan-Meier curves for overall survival in colorectal carcinomas. Kaplan-Meier curves for cumulative survival rate of patients
according to the promoter methylation in all the colorectal carcinomas. Among the ten genes, only patients with methylated WIF1 gene promoter
had shorter overall survival. M, Methylated; U,Unmethylated.
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Table 2 The relationship of DNMT1 expression with the




DNMT1-overexpressed cases Odds ratio
(CI 95%)N (%) Fold change (mean ± SD)
1 (n = 35) 13 (37.1) 1.52 ± 1.12 1
2 (n = 19) 11 (57.9) 2.12 ± 1.56 2.3 (0.7-7.2)
3 (n = 16) 9 (56.2) 2.02 ± 1.78 2.1 (0.6-7.2)
4 (n = 10) 6 (60) 3.61 ± 1.89 2.5 (0.6-10.7)
5 (n = 11) 7 (63.6) 3.06 ± 1.55 2.9 (0.7-12.9)
6 (n = 7) 6 (85.7) 4.14 ± 1.28 10.1 (1.1-93.9)*
*p value <0.05, CI, confidence interval.
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http://www.jbiomedsci.com/content/21/1/73methylation was correlated with histological type, therefore
the frequency of methylation is higher in non-mucinous
type (p = 0.001 and p = 0.025). There is no significant
association between genes methylation status and tumor
location. There is also no significant association between
DNMT1 expression and clinicopathological features.
Follow-up information was available on 112 CRC patients
for 42 ± 25 (3 to 80) months. Univariate analysis by the
Kaplan-Meier curves indicated, among the ten genes, only
WIF1 has a negative correlation between promoter methy-
lation and survival in CRC patients (P < 0.001) (Figure 1).
Correlation of DNMT1 overexpression with the increasing
number of methylated genes
We assayed the expression levels of DNMT1 enzyme
mRNA in 125 tumor and adjacent normal tissues. As
Figure 2 shows, DNMT1 expression in CRC tissues
(2.01 ± 0.82) is statistically higher than the non-tumor
mucosa (1.02 ± 0.52) (P < 0.001), as well as methylated
(2.91 ± 0.95) than non-methylated samples (1.07 ± 0.44)
(P < 0.001). We also investigated the expression levels of
DNMT1 mRNA within methylated samples and was
compared to fold changes of DNMT1 expression. For
this purpose, methylated samples were divided into six
groups according to the number of methylated genes.
The results show; the expression level of the DNMT1
mRNA was directly correlated with the increasing num-
ber of methylated genes in methylated samples (Table 2).
Discussion
Today, the epigenetic markers of causing changes in the
WNT signaling pathways are highly considered, both in
the detection and prognosis of the disease process in manyFigure 2 The expression levels of DNMT1 enzyme mRNA in
colorectal carcinomas. The level of DNMT1 expression in methylated
samples is higher than non-methylated as well as tumor samples
than non-tumor.cancers [17]. The study of methylation as a reversible major
change during the early stages of tumor angiogenesis is
under investigation [18,19]. Hence, we were going to inves-
tigate the variability of promoter methylation of WNT
negative regulators to estimate these changes in CRC. In
this study, the frequency of promoter methylation of APC
gene (35.2%) is higher than the frequency obtained during
the studies of Chen et al. (17.9%), Esteller et al. (18%)
and Arnold et al. (28%) [10,20,21]. On the other hand,
this frequency is less than the frequencies in Studies of
Iacopetta et al. (41.1%) and Fu et al. (41.7%) [22,23].
Because, changes in the APC gene are the most common
cause of CRC, 35.2% methylation can also be significant.
The AXIN2 methylation frequency of this study (32.8%)
compared to prevalence of the Koinuma et al. study (25%)
had higher level [11]. It seems that frequency of DKK3
promoter methylation (40%) is less than Yu et al. study
(52%). Unlike Yu et al. study, we reported that the increas-
ing of promoter methylation frequency was significant in
men, but we did not find a significant association between
promoter methylation frequencies with cancer progressionTable 3 The comparison of promoter methylation of this






APC 44 (35.2) Esteller et al. [21] (18%); Arnold et al. [10]
(28%); Chen et al. [20] (17.9%); Iacopetta
et al. [22] (41.1%) and Fu et al. [23] (41.7%)
AXIN2 41 (32.8) Koinuma et al. [11] (25%)
DKK3 50 (40) Yu et al. [12] (52%)
SFRP2 58 (46.4) Qi et al. [13] (82.8%)
SFRP4 38 (30.4) Qi et al. [13] (32.4%)
SFRP5 33 (26.4) Qi et al. [13] (54.3%)
SOX7 40 (32) No Reference
SOX17 42 (33.6) No Reference
WIF1 52 (41.6) Lee et al. [24] (74%)
WNT5a 28 (22.4) Rawson et al. [25] (18.8%)
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SFRP2, 4, 5 genes in this study (46.4%, 28.8%, and
26.4%) compared to the results of Qi et al. study (82.8%,
32.4% and 54.3%) is much lower [13]. Low frequency of
WIF1 promoter methylation in this study (41.6%) com-
pared to the Lee et al. study (74%) was also considerable
[24]. There are few differences between frequency of
WNT5a promoter methylation in this study (22.4%) and
Rawson et al. study (18.8%). In both studies, the frequency
of promoter methylation is significantly associated with
female gender [25] (Table 3). Univariate analysis indicates
that WIF1 promoter methylation is prognostic factors for
overall survival in colorectal carcinomas. The results of
this study show that DNMT1 expression levels in methyl-
ated samples are higher from unmethylated, unlike Ting
et al. study in which they believed the DNMT1 enzyme
has no effect on the maintenance of DNA methylation
[26]. The increasing expression of the DNMT1 enzyme
weakly correlates with the increasing number of methyl-
ated genes (Table 2). On the other hand, there have not
been many studies on correlation between DNMT1
expression and methylation, which makes it difficult to
evaluate our work; Therefore, It needs more study.Conclusions
We have shown that the rate of gene methylation in can-
cer cells increases can contribute to cancer development
and progression. Methylation may also increase due to
increased expression or mutations in the methyltransferase
enzyme or their regulatory proteins in cancer cells. Know-
ing the rate of DNMT1 enzyme overexpression in human
cancers, particularly in cases of hyper-methylated might be
useful as part of the diagnostic and prognostic evaluation
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